- 专利标题： Inhibitors for ERG oncogene positive cancers
-
申请号： US15125438申请日： 2015-03-12
-
公开(公告)号： US09782394B2公开(公告)日： 2017-10-10
- 发明人: Clifton Dalgard , Ahmed Mohamed , Meera Srivastava , Shiv Srivastava
- 申请人： The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- 申请人地址： US MD Bethesda
- 专利权人： The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- 当前专利权人： The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- 当前专利权人地址： US MD Bethesda
- 代理机构： Morgan, Lewis & Bockius LLP
- 国际申请： PCT/US2015/020172 WO 20150312
- 国际公布： WO2015/138722 WO 20150917
- 主分类号： A61K31/44
- IPC分类号： A61K31/44 ; A61K31/4402 ; C09B29/28 ; C09B67/46 ; A61K31/135 ; A61K31/136 ; A61K31/426 ; A61K45/06
摘要：
Alterations to the ERG gene are some of the most prominent genomic changes associated with many cancers including prostate cancer. Such cancer specific alterations result in the overexpression of wild type ERG protein or an altered ERG protein. The present invention provides selective inhibitors of wild type or an altered ERG protein expression. The ERG inhibitors of the invention, therefore, are therapeutic agents for treating ERG positive cancers.
公开/授权文献
- US20170071920A1 NOVEL INHIBITORS FOR ERG ONCOGENE POSITIVE CANCERS 公开/授权日：2017-03-16
信息查询
